Antimycobacterial profile of 5-phenyl-1,3,4-thiadiazole-2-arylhydrazone derivatives

Letters in Drug Design and Discovery

Volumn 7, Issue 8, 2010, Pages 606-609

  Carvalho, Samir A ^a,b   da Silva, Edson F ^a   Lourenço, Maria C S ^c   de Souza, Marcus V N ^a   Fraga, Carlos A M ^b  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c Funda??o Oswaldo Cruz   (Brazil)

Author keywords

1,3,4 thiadiazoles; Antimycobacterial activity; N arylhydrazones; Tuberculosis

Indexed keywords

5 PHENYL 1,3,4 THIADIAZOLE 2 ARYLHYDRAZONE DERIVATIVE; HYDRAZONE DERIVATIVE; ISONIAZID; RIFAMPICIN; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; DRUG INHIBITION; DRUG STRUCTURE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL;

EID: 77958541434     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018010792062768     Document Type: Article

References (29)

1. TDR: For research on diseases of poverty. Available at: http://www.who.int/tdr/diseases/tb/default.htm (Accessed Feb 6, 2010).
2. Snider Jr., D.E.; Raviglione, M.; Kochi, A. In: Tuberculosis: Pathogenesis, Protection, and Control; Bloom, B.R., Ed.; American Society of Microbiology: Washington, 1994; pp. 3-12.
3. De Souza, M.V.N. Promising drugs against tuberculosis. Recent Pat. AntiInfect. Drug Discov., 2006, 1, 33-44.
4. WHO: A world free of TB. Available at: http://www.who.int/tb/en(Accessed Feb 6, 2010).
5. Raviglione, M. XDR-TB: Entering the post-antibiotic era? Int. J. Tuberc. Lung Des., 2006, 10, 1185-1187.
6. De Souza, M.V.N. Current status and future prospects for new therapies for pulmonary tuberculosis. Curr. Opin. Pulm. Med., 2006, 12, 167-171.
7. Carvalho, S.A.; da Silva, E.F.; Santa-Rita, R.M.; de Castro, S.L.; Fraga, C.A.M. Synthesis and antitrypanosomal profile of new functionalized 1,3,4-thiadiazole-2-aryl hydrazone derivatives, designed as non-mutagenic megazol analogues. Bioorg. Med. Chem. Lett., 2004, 14, 5967-5970.
8. Carvalho, S.A.; Harrison, W.T.A.; Fraga, C.A.M.; Silva, E.F.; Wardell, J.L.; Wardell, S. M. S. V. 5-Phenyl-2-(benzalhydrazonyl)-1,3,4-thiadiazoles, potential trypanocidal agents: Consistent dimmer formation via N-H···N intermolecular hydrogen bonds. Z. Kristallogr., 2009, 224, 598-606.
9. Padmavathi, V.; Reddy, G.S.; Padmaja, A.; Kondaiah, P.; Shazia, A. Synthesis, antimicrobial and cytotoxic activities of 1,3,4-oxadiazoles, 1,3,4-thiadiazoles and 1,2,4-triazoles. Eur. J. Med. Chem., 2009, 44, 2106-2112.
10. Oruç, E.E.; Rollas, S.; Kandemirli, F.; Shvets, N.; Dimoglo, A.S. 1,3,4-Thiadiazole derivatives. synthesis, structure elucidation, and structure-antituberculosis activity relationship investigation. J. Med. Chem., 2004, 47, 6760-6767.
11. Fraga, C.A.M.; Barreiro, E.J. Medicinal chemistry of Nacylhydrazones: New lead-compounds of analgesic, antiinflammatory and antithrombotic drugs. Curr. Med. Chem., 2006, 13, 167-198.
12. Duarte, C.D.; Barreiro, E.J.; Fraga, C.A.M. Privileged structures: A useful concept for the rational design of new lead drug candidates. Mini Rev. Med. Chem., 2007, 7, 1108-1119.
13. Junior, I.N.; Lourenço, M.C.S.; Henriques, M.G.M.O.; Ferreira, B.; Vasconcelos, T.R.A.; Peralta, M.A.; de Oliveira, P.S.M.; Wardell, S.M.S.V.; de Souza, M.V.N. Synthesis and anti-mycobacterial activity of N'-[(E)-(disubstituted-phenyl)methylidene]isonicotinohydrazide derivatives. Lett. Drug Des. Discov., 2005, 2, 563-566.
14. Lourenço, M.C.S.; Ferreira, M.L.; de Souza, M.V.N.; Peralta, M.A.; Vasconcelos, T.R.A.; Henriques, M. G. M. O. Synthesis and anti-mycobacterial activity of (E)-N'-(monosubstitutedbenzylidene) isonicotinohydrazide derivatives. Eur. J. Med. Chem., 2008, 43, 1344-1347.
15. -1.
16. Canetti, G.; Fox, W.; Khomenko, A.; Mahler, H.T.; Menon, N.K.; Mitchison, D.A.; Rist, N.; Smelev, N.A. Advances in techniques of testing mycobacterial drug sensitivity, and the use of sensitivity tests in tuberculosis control programmes. Bull. World Health Organ., 1969; 41, 21-43.
17. Franzblau, S.G.; Witzig, R.S.; McLaughlin, J.C.; Torres, P.; Madico, G.; Hernandez, A.; Degnan, M.T.; Cook, M.B.; Quenzer, V.K.; Ferguson, R.M.; Gilman, R.H. Rapid, low-technology MIC determination with clinical Mycobacterium tuberculosis isolates by using the microplate Alamar Blue assay. J. Clin. Microbiol., 1998, 36, 362-366.
18. Vanitha, J.D.; Paramasivan, C.N. Evaluation of microplate Alamar blue assay for drug susceptibility testing of Mycobacterium avium complex isolates. Diagn. Microbiol. Infect. Dis., 2004, 49, 179-182.
19. Reis, R.S.; Neves, I. Jr.; Lourenço, S.L.S.; Fonseca, L.S.; Lourenço, M.C.S. Comparison of flow cytometric and alamar blue tests with the proportional method for testing susceptibility of mycobacterium tuberculosis to rifampin and isoniazid. J. Clin. Microbiol., 2004, 42, 2247-2248.
20. Richardson, D.R.; Hefter, G.T.; May, P.M.; Webb, J.; Baker, E. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. III. Formation constants with calcium(II), magnesium(II) and zinc(II). Biol. Met., 1989, 2, 161-167.
21. Richardson, D.R.; Tran, E.; Ponka, R. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood, 1995, 86, 4295-4306.
22. Richardson, D.R.; Milnes, K. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents II: The mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood, 1997, 89, 3025-3038.
23. Richardson, D.R. Cytotoxic analogs of the iron(III) chelator pyridoxal isonicotinoyl hydrazone: Effects of complexation with copper(II), gallium(III), and iron (III) on their antiproliferative activities. Antimicrob. Agents Chemother., 1997, 41, 2061-2063.
24. Vitolo, L.M.W.; Hefter, G.T.; Clare, B.W.; Webb, J. Iron chelators of the pyridoxal isonicotinoyl hydrazone class Part 2. Formation constants with iron(III) and iron(II). Inorg. Chim. Acta, 1990, 170, 171-174.
25. Jordan, A.; Reichard, P. Ribonucleotide reductases. Annu. Rev. Biochem., 1998, 67, 71-98.
26. Cerqueira, N.M.; Pereira, S.; Fernandes, P.A.; Ramos, M.J. Overview of ribonucleotide reductase inhibitors: An appealing target in anti-tumour therapy. Curr. Med. Chem., 2005, 12, 1283-1294.
27. Wnuk, S.F.; Robins M.J. Ribonucleotide reductase inhibitors as anti-herpes agents. Antiviral Res., 2006, 71, 122-126.
28. Sassetti, C.M; Boyd, D.H.; Rubin, E.J. Genes required for mycobacterial growth defined by high density mutagenesis. Mol. Microbiol., 2003, 48, 77-84.
29. Dawess, S.S.; Warner, D.F.; Tsenova, L.; Timm, J.; McKinney, J.D.; Kaplan, G.; Rubin, H.; Mizrahi, V. Ribonucleotide reduction in Mycobacterium tuberculosis: Function and expression of genes encoding class Ib and class II ribonucleotide reductases. Infec. Immun., 2003, 71, 6124-6131.